Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

CAR T cell therapy

This page shows the latest CAR T cell therapy news and features for those working in and with pharma, biotech and healthcare.

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

The trial included a broad range of patients, including those previously treated with a bispecific antibody or CAR-T cell therapy. ... patients in this clinical trial, which included patients treated with prior BCMA-targeted bispecific or CAR-T cell

Latest news

More from news
Approximately 7 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • Gene therapy, gene editing and perspectives on future use in Parkinson’s disease Gene therapy, gene editing and perspectives on future use in Parkinson’s disease

    Vertex, who produce the therapy, has regulatory submissions underway in the USA and EU for sickle cell anaemia and β thalassaemia – the patient’s own cells are edited outside the body ... a disease – examples include CAR T-cell therapies.

  • CAR-T cell therapy in oncology CAR-T cell therapy in oncology

    Next generation CAR-T cell therapy. First generation, autologous CAR-T cell immunotherapies have demonstrated significant clinical promise. ... However, it is well recognised that the full potential of CAR-T cell therapy has yet to be fully exploited.

  • Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world Think fast, be different: succeeding at speed chess in 2021’s COVID-19 world

    EBCs also demonstrate positive data and are bringing novel therapies to market in complex areas of medicine, including gene therapy, CAR T-cell therapy and rare diseases. ... These visuals got the message across in an engaging, novel and efficient manner

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    Chimeric antigen receptor T-cell therapy. Chimeric antigen receptor (CAR) T-cell therapy consists of engineering receptors in the body that selectively interact with cancer cells, inducing cell death without affecting ... CAR-T therapy has potential

  • Cell and gene therapy Cell and gene therapy

    In addition, as Eric Althoff from Swiss pharmaceutical firm Novartis points out, making a patient-specific product like a CAR-T therapy is very different from producing a volume drug. ... We estimate the cost [of making a CAR-T cell therapy for a single

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Article: War in the Blood - The battle takes shape in the burgeoning European oncology CAR-T market access space

    I have a vivid memory of watching War in the Blood, a 2019 feature-length BBC documentary about CAR-T cell therapy and the potentially revolutionary impact on the landscape of ... We discuss their feedback and the ramifications below. We also share

  • Precision versus personalised medicine Precision versus personalised medicine

    Targeted therapy’ is a broad term that often refers to the use of drugs that target specific proteins, cell surface molecules, or genes. ... ESMO Daily Reporter. CAR-T-cell therapy. Available at: . Accessed November 2022. Qin VM, et al. Cancers

  • Understanding the evolving CAR-T market

    In August 2017, Novartis made history after receiving FDA approval for Kymriah, the world’s first chimeric antigen receptor T-cell (CAR-T) therapy. ... Today, the CAR-T market is expected to increase at an annual rate of 30% until 2030.

  • Precision paediatrics: Treating patients with CAR-T

    He is part of a team using a groundbreaking chimeric antigen receptor T-cell (CAR-T) therapy, which is transforming outcomes for children who would otherwise have no treatment options left. ... SA: CAR-T cell therapy is an innovative immunotherapy that

  • Highlights in haematologic malignancy from ASH 2018

    The spotlight shone on Chimeric Antigen Receptor(CAR) T-cell therapy; a transformative approach where the patient’s T cells are harvested and re-engineered to recognise antigens expressed by the ... A reduced risk of relapse was also seen when

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....

Quick links